Sustainability Initiatives

• Providing a stable supply of pharmaceuticals
• Pursuit of safe and reliable quality

We prioritize product reliability and stable supply to meet the growing demand for pharmaceuticals and vaccines. By doing so, we consistently provide high-quality pharmaceuticals to protect people's health and safety.

• Ensuring strict compliance
• Strengthening corporate governance

We comply with all laws and regulations and conduct regular training to ensure that all employees act ethically.
Additionally, we realize highly reliable business operations by strengthening the appropriate management of information assets and striving to protect confidential information.
In addition, to ensure management transparency, we have established effective corporate governance and built a structure to integrate diverse viewpoints into our business strategy.
In the area of labor management, we emphasize employee well-being and make efforts to improve health management and the working environment.

• Building relationships of trust with customers

Starting in 2023, we expanded our business to include pharmaceutical contract manufacturing (CMO).
By offering flexible and comprehensive services that meet client needs, we are building new partnerships.
We are committed to making even greater efforts to protect the health of people not only in Japan but across the world.

• Local environmental initiatives

In order to protect the precious natural beauty of the region, we actively participate in cleanup activities around Odawara Castle and the Sakawa River.
In addition, we hold a Clean Day twice a year, where all employees participate in cleanup activities both inside the facility and along the local roads surrounding the company.
We will continue our efforts to pass on the beautiful nature of Odawara to future generations.
To protect the "medaka" (Japanese rice fish) native to the Sakawa River system from extinction, we also participate in the "Medaka Parent Program" (Medaka no Otousan Okaasan Seido).
We contribute to local environmental preservation by carefully protecting and connecting these vulnerable lives.

• Waste reduction
• CO2 reduction

To reduce waste, we recycle a variety of materials, including aluminum cans used to transport active pharmaceutical ingredients and polydrums used for shipping tablets from overseas.
For example, by recycling plastic pallets used for storing and transporting drugs, we have reduced CO2 by about 17 tonnes per year.
In addition to these efforts, we have engaged in various other energy-saving activities and were certified as an S-Class (Excellent Energy-Saving Business) under the Energy Conservation Act's SABC Classification System for FY2024.
We will continue our efforts to protect the environment in order to realize a sustainable society.

• Realizing growth

We create a workplace where our employees are driven by a sense of purpose and contribute meaningfully to public health.
We value our employees' integrity and motivation for growth, promoting their career advancement by offering opportunities for external training and providing certification support programs.
Our goal is to ensure employees achieve personal growth, with their resulting achievements contributing to the overall development of the organization.

• Respect for diversity

Approximately 60% of our employees are women, and we are actively working to promote the employment of women.
We also actively encourage employees to use the flexitime system for childcare and promote the utilization of paternity leave by men.
We respect diverse values and strive to create an inclusive workplace where all employees can work productively and comfortably.

• Manufacturing new drugs

Leveraging the extensive experience and exceptional technical expertise cultivated as a member of the meiji Group, we are committed to manufacturing new drugs that require advanced technological standards and ensuring the stable supply of long-awaited new drugs that address Unmet Medical Needs.

• Antimicrobial Resistance (AMR) measures

We provide comprehensive support from investigational new drugs to commercial manufacturing of new antibiotics to address AMR (drug resistance).

• Clinical trial drug manufacturing support

In our Contract Manufacturing business, we provide comprehensive, end-to-end support for the formulation process of injectables, covering everything from process development studies and pilot manufacturing to clinical trial drug manufacturing.
In addition, we optimize manufacturing conditions in the formulation process for oral solid dosage forms and provide a wide range of support—from investigational drug manufacturing to commercial-scale up—to support our clients' challenges in new modalities.
By providing options for new modalities, we will continue to contribute to improving patients' Quality of Life (QOL) and advancing medical care.